ongoing Phase 1b

Related by string. * ONGOING . ON GOING . ONGOER . Ongoing . Ongo : ONGOING Bellevue Botanical Garden . ongoing marital discord . Ongoing De Pere . Ongoing Storefronts recreate . Ongoing exhibits / phase . phases . Phases . PHASE . PHASES : Phase III clinical trials . Phase III trials . Phase III clinical . Phase 2b clinical / 1Bs . 1B : 1B Todd Helton . 1B Adam LaRoche . H 1B visas . H 1B visa * *

Related by context. All words. (Click for frequent words.) 75 randomized controlled Phase 74 Phase Ib study 74 evaluating tivozanib 73 BRIM2 73 BRIM3 73 Phase Ib clinical 73 phase IIa clinical 73 virus HCV protease inhibitor 73 phase IIb clinical 73 Phase Ib II 72 Phase 1b clinical 72 multicenter Phase II 72 Phase 1a clinical 72 Phase 1b 72 Randomized Phase 72 oral ridaforolimus 72 phase Ib 72 trastuzumab DM1 T DM1 71 Initiated Phase 71 dose escalation clinical 71 Phase #b/#a clinical 71 temsirolimus Torisel ® 71 BR.# 71 PDX pralatrexate 71 randomized Phase 2b 71 alvespimycin 71 refractory chronic lymphocytic 71 placebo controlled Phase 70 Phase 2a trial 70 Initiate Phase 70 randomized Phase III 70 multicenter Phase 70 HGS ETR2 70 fidaxomicin Phase 3 70 Phase 1b trial 70 PSMA ADC 70 Randomized Phase II 70 adecatumumab MT# 70 phase IIb study 70 Amrubicin 70 ganetespib 70 phase IIb 69 AVOREN 69 Cloretazine ® 69 Phase #/#a 69 phase 2a 69 adecatumumab 69 neratinib 69 BCIRG 69 FOLOTYN ® 69 SUCCEED trial 69 blinded randomized placebo controlled 69 dose escalation Phase 69 HCV SPRINT 69 Panzem R NCD 69 Pivotal Phase III 69 axitinib 69 ORAL Sync 69 FOLFOX6 chemotherapy regimen 69 IMPACT DCM 69 PEG SN# 69 LUX Lung 69 HGS ETR1 69 crizotinib PF # 69 INCB# [001] 69 Phase Ib 69 pharmacokinetic PK 68 oral prodrug 68 SCH # 68 Phase IIIb clinical 68 Aflibercept 68 randomized Phase IIb 68 forodesine 68 relapsed refractory multiple myeloma 68 dose escalation trial 68 Pivotal Phase 68 treatment naive genotype 68 multicenter randomized controlled 68 initiate Phase 1b 68 huC# DM4 68 MAGE A3 ASCI 68 multicenter randomized Phase 68 Phase 2a clinical 68 CR# vcMMAE 68 multicenter Phase III 68 EOquin TM 68 Glufosfamide 68 HuMax EGFr 68 EVEREST II 68 registrational Phase 68 liposomal formulation 68 Traficet EN 68 phase IIa 68 Tarceva TM 68 TMC# C# 68 #th Annual Interscience 68 Phase 2b clinical 68 viral kinetic 68 Allovectin 7 ® 68 galiximab 68 perifosine KRX 68 Phase Ib IIa 68 CEQ# 68 Androxal TM 68 novel VDA molecule 68 randomized discontinuation trial 68 relapsed MM 68 non nucleoside inhibitor 67 anticancer compound 67 histone deacetylase HDAC inhibitor 67 PI3K/Akt pathway inhibitor 67 mapatumumab 67 fidaxomicin Phase 67 PANVAC VF 67 Society CTOS 67 Phase 2b study 67 solithromycin 67 randomized controlled multicenter 67 elotuzumab 67 assessing T DM1 67 Phase 2a 67 Phase IIIb 67 pomalidomide 67 PRECiSE 67 Zybrestat 67 ENDEAVOR III 67 Prostate AdenoCarcinoma Treatment 67 Phase III VISTA 67 NSABP B 67 PrevOnco 67 orally administered inhibitor 67 EXPLORE Xa 67 Panzem NCD 67 Sym# 67 interferon gamma 1b 67 XL# SAR# 67 Phase 2b Clinical Trial 67 Combination REOLYSIN R 67 NO# [002] 67 multicenter phase 67 multicenter randomized placebo controlled 67 HGS# 67 midstage clinical 67 fosbretabulin 67 ELACYT 67 OncoVEX GM CSF 67 Phase 1b clinical trials 67 Phase III placebo controlled 67 radiation sensitizer 67 trastuzumab emtansine T DM1 67 metastatic castration resistant 67 ToGA 67 LymphoStat B TM 67 pralatrexate 66 telomerase inhibitor drug 66 Phase III randomized controlled 66 dose cohort 66 APEX PD 66 Genasense ® oblimersen 66 docetaxel Taxotere R 66 pan HDAC inhibitor 66 HCV RESPOND 2 66 AVADO 66 phase IIb trial 66 vidofludimus 66 placebo controlled clinical 66 #nd EORTC NCI 66 lintuzumab SGN 66 HER2 positive metastatic breast 66 Quinamed 66 MGd 66 treatment naïve genotype 66 GLP toxicology studies 66 Matrix Phase 2b 66 Phase #/#a trial 66 Phase III Pivotal 66 brivanib 66 FOLFOX6 66 Aplidin R 66 Phase III psoriasis 66 ZYBRESTAT TM 66 depsipeptide 66 Omacetaxine 66 placebo controlled Phase III 66 seliciclib CYC# 66 PRT# 66 phase Ib clinical 66 evaluating satraplatin 66 GRNVAC1 66 nab paclitaxel 66 Phase 2b Study 66 prospective multicenter 66 AACR NCI EORTC 66 Connective Tissue Oncology 66 satraplatin Phase 66 ENDEAVOR IV 66 Albuferon TM 66 rNAPc2 66 Phase III ALLEGRO 66 tenofovir emtricitabine 66 pharmacokinetic PK study 66 GAMMAGARD 66 evaluating Prochymal 66 systemic anaplastic large 66 Phase IIa trial 66 APPRAISE 66 recurrent glioblastoma multiforme 66 metastatic hormone refractory 66 VEGFR2 inhibitor 66 generation purine nucleoside 66 Cimzia ® certolizumab pegol 66 Solorel TM 66 Azedra 65 ADVANCE PD 65 Aplidin 65 volociximab 65 PROVENGE ® 65 Vitaxin 65 Randomized Double Blind 65 XL# XL# XL# 65 pertuzumab 65 metastatic castrate resistant 65 double blinded randomized 65 teriflunomide 65 dose cohorts 65 Phase IIb III 65 HGS ETR1 mapatumumab 65 acyclovir Lauriad R 65 Alocrest 65 mertansine 65 ocular formulation 65 Hsp# Inhibitor 65 huN# DM1 65 romidepsin 65 metastatic HRPC 65 CCX# 65 PrevOnco ™ 65 SABCS 65 metastatic CRC 65 Completes Patient Enrollment 65 R#/MEM # 65 phase IIb III 65 Phase 2b kidney transplant 65 investigational oral hepatitis C 65 ASCO abstract 65 DASISION 65 CALGB # [002] 65 Phase 2a clinical trials 65 multicentre randomized 65 ThermoDox R 65 Phase 1b dose escalation 65 daily Infergen 65 APOPTONE 65 Metastatic Melanoma 65 subcutaneous PRO 65 tanespimycin 65 Phase IIa clinical 65 OvaRex ® MAb 65 VNP#M 65 Initiates Phase II 65 farletuzumab 65 sorafenib tablets 65 CTAP# Capsules 65 NVA# 65 Trofex 65 CAMMS# 65 RECORD1 65 compound INCB# 65 unblinding 65 enzastaurin 65 Panzem R 65 AEG# 65 telomerase therapeutic 65 Carfilzomib 65 dasatinib Sprycel ® 65 Safinamide 65 PROSTVAC TM 65 resectable pancreatic cancer 65 sorafenib Nexavar ® 65 Xelox 65 GOUT 65 ExTRACT TIMI 65 entinostat 65 CIMZIA TM certolizumab pegol 65 Clinical Trial Results 65 Diabetic Macular Edema DME 65 HCD# [002] 65 CBLC# 65 investigational protease inhibitor 65 Tanespimycin 65 elacytarabine 65 Oral Fingolimod 65 phase IIIb 65 preclinical efficacy 65 PROVENGE sipuleucel T 65 YONDELIS 65 Phase 2b 65 including eniluracil ADH 65 QLT# 65 small molecule Hedgehog 65 ThermoDox ® clinical 65 sunitinib malate 65 initiated Phase Ib 65 ZACTIMA 65 preclinical pharmacokinetic 65 investigational humanized monoclonal antibody 65 TLK# 64 Annamycin 64 Aurexis 64 confirmatory Phase 3 64 Brentuximab Vedotin SGN 64 viral kinetics 64 Active Ulcerative Colitis 64 PEG IFN 64 Kahalalide F 64 Cannabinor 64 investigational antiplatelet agent 64 multicenter placebo controlled 64 refractory cutaneous T 64 Phase 2b randomized 64 Clinical Oncology Annual Meeting 64 HuMax CD4 64 TG MV 64 Pegasys ® 64 MEND CABG 64 confirmatory clinical 64 alkylating agent 64 Cloretazine 64 IFN α 64 Phase IIb clinical 64 PSN# [002] 64 gemcitabine Gemzar ® 64 refractory multiple myeloma 64 RGB # 64 Seliciclib 64 Randomized Double blind 64 SPIRIT FIRST 64 mGluR5 negative 64 evaluating Vectibix 64 EGFR HER2 64 AP# [003] 64 double blinded placebo 64 Pralatrexate 64 demonstrated antitumor activity 64 Elotuzumab 64 PNP inhibitor 64 randomized Phase 64 FOLFIRI chemotherapy 64 imetelstat GRN#L 64 PROTECT AF 64 label dose escalation 64 CYT# potent vascular disrupting 64 IMA# 64 Corlux 64 oral picoplatin 64 rALLy clinical trial 64 IL# PE#QQR 64 ritonavir boosted 64 vascular disrupting agent 64 GVAX ® 64 deforolimus 64 dependent kinase inhibitor 64 OMP #M# 64 ENESTnd 64 PD LID 64 Dacogen injection 64 ACTEMRA TM 64 Xanafide 64 CUSTOM III 64 ceftazidime 64 evaluating Actimmune 64 Tesetaxel 64 BiTE R 64 evaluating picoplatin 64 Enzastaurin 64 GVAX R 64 velafermin 64 Investigational Oral 64 delafloxacin 64 TAXUS ATLAS 64 sNDA submission 64 Genasense R oblimersen 64 LBH# 64 nitazoxanide 64 MEK Inhibitor 64 initiated Phase 1b 64 XmAb# 64 pharmacokinetics PK 64 TACI Ig 64 dose escalation phase 64 thalidomide Thalomid 64 Proxinium TM 64 XYOTAX TM 64 Sapacitabine 64 pivotal bioequivalence 64 EmbraceAC 64 CLL SLL 64 registrational trial 64 advanced metastatic renal 64 sapacitabine 64 oral rivaroxaban 64 multicenter randomized double 64 evaluating Xcytrin 64 CYT# 64 systemically administered 64 CLARITY study 64 Zenvia TM 64 Phase 2b trial 64 controlled multicenter Phase 64 Medullary Thyroid Cancer 64 Cloretazine R VNP#M 64 metastatic GIST 64 PRTX 64 ospemifene 64 riociguat 64 Late Breaker 64 MOZOBIL 64 designated HVTN 64 Tezampanel 64 DermaVir Patch 64 Phase III AFFIRM 64 Hormone Refractory Prostate Cancer 64 Hedgehog Pathway Inhibitor 64 ASCO GI 64 relapsed multiple myeloma 64 Phase 1a 64 Phase #b/#a trial 64 SPRYCEL ® 64 IRX 2 64 lenalidomide Revlimid ® 64 Phase III Clinical Trial 64 Phase IIB 64 cisplatin gemcitabine 64 Rigel R# 64 evaluating carfilzomib 64 isatoribine 64 telaprevir VX 64 RAV# 64 Phenoptin 64 brivaracetam 64 Maximum Tolerated Dose MTD 64 mTOR inhibitor 64 Anturol TM 64 Phase III confirmatory 64 SAR# [004] 64 sunitinib Sutent ® 64 TELCYTA 64 prospectively defined 64 Study Evaluating 64 R# #mg BID 64 Phase III ADT 64 Personalized Immunotherapy 64 Cloretazine R 64 UPLYSO 64 JAK inhibitor 64 TORISEL TM 64 fallopian tube cancers 64 tramiprosate Alzhemed TM 64 Genasense ® 64 GENASIS clinical 64 IgG1 monoclonal antibody 64 BRAF inhibitor 64 TBC# 64 MGCD# [001] 64 GW# [003] 64 BOLDER II 64 PRE SURGE 64 bortezomib Velcade 64 tumor xenograft models 64 Phase III randomized 64 Exherin TM 64 Bayer HealthCare Onyx Pharmaceuticals 63 HDAC Inhibitor 63 active comparator 63 Zenvia Phase III 63 ALN VSP Phase 63 Phase Ib clinical trials 63 ponatinib 63 CLORETAZINE TM VNP#M 63 investigational pan BCR 63 ENMD # 63 papillary renal cell carcinoma 63 platinum refractory 63 Bezielle 63 Archexin 63 Phase III clinical 63 Phase III multicenter 63 CCR5 mAb 63 reslizumab 63 ORENCIA ® 63 Acute Ischemic Stroke 63 Vicinium TM 63 Chemophase 63 AVERROES 63 candidate CRLX# 63 Xcellerated T Cells 63 G#DT 63 XL# XL# 63 Romidepsin 63 CRLX# 63 COU AA 63 ORACLE MS 63 evaluating mipomersen 63 recurrent malignant glioma 63 SPIRIT IV 63 registrational 63 Xeloda ® 63 erlotinib Tarceva ® 63 BiTE antibody MT# 63 generation Hsp# inhibitor 63 CRMD# 63 NASDAQ CXSP announced 63 prospective multicenter randomized 63 proteasome inhibitor 63 GALNS 63 cetuximab Erbitux 63 CIMZIA TM 63 Phase #b/#a 63 HCV protease inhibitor 63 Augment Injectable 63 thorough QT 63 Phase IIb Trial 63 EURIDIS 63 Phase III pivotal 63 sodium thiosulfate STS 63 PERSEUS 63 REG1 Anticoagulation System 63 CoFactor 63 Gastrointestinal Cancers Symposium 63 CLL8 63 Cell Lymphoma 63 Velcade bortezomib 63 AASLD Meeting 63 ruxolitinib 63 Vidaza ® 63 EDEMA3 63 receptor tyrosine kinase inhibitor 63 label multicenter Phase 63 Elagolix 63 lesinurad 63 rALLy trial 63 radezolid 63 rapid virologic response 63 initiate Phase Ib 63 cediranib 63 Voreloxin 63 mitogen activated ERK kinase 63 PreCISe 63 Meets Primary Endpoint 63 investigational monoclonal antibody 63 dosing cohorts 63 HCV NS5B polymerase 63 BAY #-# 63 Randomized Phase III 63 GetGoal Phase III 63 Allovectin 7 63 MERLIN TIMI 63 q8h 63 eniluracil 63 Lenocta 63 ZOLINZA 63 GRN#L 63 Pooled Analysis 63 Entereg R 63 CIMZIA ™ 63 Phase III ThermoDox 63 nonrandomized 63 L BLP# 63 Phase Ia 63 IIa trial 63 VELCADE melphalan 63 ZYBRESTAT fosbretabulin 63 ZYBRESTAT 63 FavId 63 PS# [001] 63 ROCKET AF 63 evaluating T DM1 63 Initiates Clinical 63 Randomised 63 Presents Preclinical Data 63 Phase IIb clinical trials 63 Azedra ™ 63 Vascular Disrupting Agent 63 antibody MAb 63 Proellex TM 63 lorvotuzumab mertansine 63 sunitinib Sutent 63 Boceprevir 63 safety tolerability pharmacokinetic 63 PHX# 63 pivotal Phase 63 Urocortin 2 63 Curaxin CBLC# 63 Ophena 63 sorafenib Nexavar 63 Deforolimus 63 antibody blinatumomab MT#/MEDI-# 63 Vicriviroc 63 EGS# 63 Reolysin 63 tolevamer 63 CALGB 63 DIRECT Trial 63 OncoVex 63 CA4P 63 nonclinical studies 63 bortezomib Velcade R 63 paclitaxel Taxol R 63 IMGN# 63 PXD# 63 subcutaneous formulation 63 PRIMO CABG 63 lumiliximab 63 randomized multicenter 63 Pivotal Phase II 63 Plicera 63 CDK inhibitor 63 AEGR 63 TRAIL R1 63 sodium glucose cotransporter 63 palifosfamide Zymafos TM 63 docetaxel Taxotere ® 63 AVN# Phase 63 Edge STudy 63 trastuzumab DM1 63 brentuximab vedotin SGN 63 Perifosine 63 investigational immunotherapy 63 5 fluorouracil leucovorin 63 Presents Positive 63 Telavancin 63 Pemetrexed 63 Presents Preclinical 63 gemcitabine cisplatin 63 RNAi Therapeutic 63 Alzhemed TM 63 eosinophilic asthma 63 Ceflatonin 63 Telatinib 63 NASDAQ CYTK announced 63 refractory gout 63 TASKi2 63 LymphoStat B belimumab 63 PFO migraine 63 IMC #B 63 PEG Interferon lambda 63 Imprime PGG 63 aflibercept 63 label multicenter randomized 63 IMPACT IMmunotherapy 63 systemic RNAi therapeutic 63 BLP# Liposome Vaccine 63 docetaxel chemotherapy 63 orally bioavailable 63 Tarvacin TM 63 AKT inhibitor 63 Targretin capsules 63 Commences Phase 63 BCX# 63 Dasatinib 63 maximally tolerated dose 63 next generation URAT1 63 Nasdaq PGNX today 63 DEB# 62 PCI ExTRACT TIMI 62 Pharmacodynamic 62 Locteron ® 62 Allovectin 7 R 62 dosing cohort 62 Pegasys plus Copegus 62 MDV# 62 Folfox 62 metaglidasen 62 castrate resistant prostate cancer 62 Dapagliflozin 62 SinuNase TM 62 Epratuzumab 62 Sudhir Agrawal D.Phil 62 nucleotide analog 62 pegylated liposomal doxorubicin 62 catheter occlusion 62 hA# 62 ribavirin RBV 62 clevidipine 62 MKC# MT 62 PF # [001] 62 multicenter multinational 62 Begins Dosing 62 #I TM# 62 hyaluronidase enzyme 62 CB2 selective receptor agonist 62 trastuzumab Herceptin R 62 ACAPODENE 62 Initiates Enrollment 62 SUTENT ® 62 KRAS mutations occur 62 multicenter randomized 62 Telik logo TELINTRA 62 MEK inhibitor RDEA# 62 Triapine R 62 GEM OS2 62 ascending dose 62 alfa 2a 62 MEND CABG II 62 PEGylated interferon beta 1a 62 pivotal Phase III 62 sarcoma melanoma 62 confirmatory Phase III 62 Zenvia ™ 62 Dacogen decitabine 62 CD# CEA 62 pegylated interferon alpha 62 IMiDs ® 62 Phase IIb 62 CML CP 62 Degarelix 62 LHRH receptor positive 62 prospective randomized placebo 62 INCB# [002] 62 severe hypercholesterolemia 62 selective androgen receptor modulator 62 thymalfasin 62 pan histone deacetylase 62 intravenous methylnaltrexone 62 Azedra TM 62 PRIMO CABG2 62 oral deforolimus 62 IMiDs ® compound 62 Long Lesion 62 R roscovitine 62 oral antiviral 62 Initiates Phase III 62 Darinaparsin 62 ECASS 62 sapacitabine CYC# 62 prospective randomized multicenter 62 Pafuramidine 62 lintuzumab 62 temsirolimus 62 CCR5 antagonist 62 IMPDH inhibitor 62 number NCT# ClinicalTrials.gov 62 TKB# 62 Rindopepimut 62 cell lymphoma CTCL 62 Preclinical Data 62 Vidaza azacitidine 62 Phase 2a Study 62 Pharmacokinetics PK 62 CLARITY TIMI 62 oral nucleoside analogue 62 retaspimycin 62 taxane resistant 62 TPI ASM8 62 low dose cytarabine 62 metastatic renal cell carcinoma 62 NEUVENGE 62 Advaxis Phase 62 Apoptone 62 cariprazine 62 Achieves Primary Endpoint 62 vinca alkaloid 62 hematological tumors 62 administered subcutaneously 62 prucalopride 62 Clolar ® 62 CATIE AD 62 Ophena TM 62 intravesical infusion therapy 62 Sorafenib HCC Assessment 62 GAP #B# 62 COMFORT II 62 Bortezomib 62 MVax R 62 Prospective Randomized 62 fluoropyrimidine 62 ACCEDE 62 plus Copegus R 62 Actilon 62 targeted radiotherapeutic 62 ALN TTR 62 2 methoxyestradiol 62 NXL# 62 ABSORB trial 62 mCRC patients 62 cetuximab Erbitux R 62 pharmacokinetic pharmacodynamic 62 multicenter prospective 62 CCX# B 62 REVIVE Diabetes 62 prospective multicentre 62 Phase 2a Clinical Trial 62 Onconase 62 nucleoside analog 62 glufosfamide 62 AS# amonafide L malate 62 orally inhaled migraine 62 ABCSG 62 RCW breast cancer 62 visilizumab 62 Initiates Phase 2b 62 Second Pivotal Phase 62 metastatic malignant 62 II Clinical Trial 62 intratumoural 62 NEUGENE antisense 62 evaluable subjects 62 lucinactant 62 ZK EPO 62 Kamada AAT 62 sodium Injection 62 refractory APL 62 lomitapide 62 MIVI III 62 desvenlafaxine succinate 62 LUMINATE 62 Nexavar sorafenib 62 EndoTAG TM -1 62 Clinical Antipsychotic Trials 62 non nucleoside HCV 62 lenalidomide Revlimid R 62 ILLUMINATE 62 Phase III Clinical Trials 62 bardoxolone 62 davunetide intranasal AL 62 investigational HCV polymerase 62 multi kinase inhibitor 62 Antibody Drug Conjugate 62 TransVax tm 62 boosted protease inhibitor 62 gastrointestinal stromal tumor GIST 62 trial evaluating PRX# 62 rilonacept 62 Phase Ib Clinical Trial 62 alemtuzumab Campath 62 controlled multicenter 62 blinded randomized 62 adjuvant GIST 62 Virologic 62 LAB CGRP 62 OXi# 62 OvaRex R 62 SYN# 62 neoadjuvant 62 Solazed 62 metastatic renal cell 62 NCCTG 62 Chronic Hepatitis C 62 investigational hepatitis C 62 XOMA 3AB 62 Antiviral Activity 62 Forodesine HCl 62 seliciclib 62 mRCC 62 5 FU leucovorin 62 Pre RELAX AHF 62 ASCO Annual Meeting 62 Pivotal Study 62 Sprycel dasatinib 62 humanized interleukin 6 62 paclitaxel Taxol ® 62 PDE4 inhibitor 62 lexidronam injection 62 Initiate Phase III 62 YONDELIS R 62 tolerability pharmacokinetics 62 pain palliation 62 abacavir lamivudine 62 Successfully Completes Phase 62 TO AVOID PREGNANCY WHILE 62 phase III isavuconazole 62 bevacizumab Avastin ® 62 PROSTVAC VF 62 NSABP C 62 Placebo Controlled Trial 62 compound AEZS 62 cilengitide 62 XL# XL# XL# XL# 62 RAPTIVA 62 decitabine 62 RE SURGE 62 paclitaxel poliglumex 62 selective kinase inhibitor 62 H#N# VLP vaccine 62 imetelstat 62 Ozarelix 62 masked placebo controlled 62 Zemplar Capsules 62 Thiarabine 62 nucleotide analogue 62 Phase IIa 62 estramustine 62 AVASTIN 62 APTIVUS 62 favorable pharmacokinetic profile 62 OHR/AVR# 62 peginterferon alpha 2a 62 SinuNase ™ 62 TTF Therapy 62 angiogenesis inhibitor 62 KRN# 62 mg/m2 dose 62 liposomal doxorubicin 62 Daclizumab 62 Virulizin ® 62 OMP #R# 62 novel histone deacetylase 62 multicenter clinical 62 TRO# 62 oral FTY# 62 subcutaneously administered 61 KNS # 61 ongoing Phase IIIb 61 Pharmacokinetic PK 61 randomized multicenter trial 61 Phase IIIb study 61 Metastatic Colorectal Cancer 61 XL# anticancer compounds 61 Phase 2b monotherapy 61 EGFR TKI 61 capecitabine Xeloda R 61 ON #.Na 61 Cetuximab Erbitux 61 Teriflunomide 61 HQK 61 Natalizumab 61 HuLuc# 61 lymphoid malignancies 61 dose dose escalation 61 Solid Tumors 61 peginesatide 61 Nymox NX 61 Vidaza R 61 hepatocellular cancer 61 Pyridorin TM 61 alefacept 61 MT# MEDI 61 topoisomerase II inhibitor 61 RG# [001] 61 Genz # 61 CANCIDAS 61 bendamustine 61 Relapsed Multiple Myeloma 61 Targretin 61 stage IIIB 61 Protease Inhibitor 61 Pivotal Trial 61 Calcium Acetate 61 dextromethorphan quinidine 61 biliary tract cancer 61 trodusquemine 61 Genasense oblimersen sodium Injection 61 Immunotherapeutic 61 PF # [002] 61 BARACLUDE R 61 RE LY 61 Trial Evaluating 61 Clevudine 61 talabostat 61 ATL# [001] 61 Tyrima 61 essential thrombocythemia ET 61 ixabepilone 61 refractory CLL 61 azilsartan medoxomil 61 ara C 61 RE LY ® 61 bevacizumab Avastin R 61 carboplatin paclitaxel 61 Phase IIb trials 61 generation PNP inhibitor 61 relapsed myeloma 61 Taxotere ® 61 IND submission 61 Cutaneous T 61 Novel Oral 61 Diabetic Macular Edema 61 Solorel 61 ZD# [001] 61 Vascugel 61 recurrent metastatic 61 eliglustat tartrate 61 generation antisense inhibitor 61 ancrod 61 oral chemotherapeutic agent 61 dose escalation 61 sipuleucel T 61 TOLAMBA 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 Cethromycin 61 plus dexamethasone 61 EORTC NCI AACR Symposium 61 omacetaxine mepesuccinate 61 T Pred 61 PARTNER Trial 61 DB# [003] 61 plus dacarbazine 61 selective modulator 61 Aclidinium

Back to home page